Establishing the first southern Chinese haplobank of clinical-grade hiPSCs

Human pluripotent stem cells (PSCs) and their derivatives hold great potential in regenerative cell therapies. Establishing GMP-compliant PSC banks is a critical step in the manufacturing processes of PSC-derived cell products.

In this webinar, Camie Chan will discuss how cell therapies have emerged as a promising next-generation modality for many incurable diseases. In her talk on “Establishing the first southern Chinese haplobank of clinical-grade hiPSCs”, she will illustrate how Xellera has established the first commercial cGMP facility for cell and gene products in Hong Kong. By analyzing the HLA diversity of the southern Chinese population, Xellera has identified donors that are homozygous for the most frequent HLA-A,B,C, and DRB1 combination. The top seven human induced pluripotent stem cell (hiPSC) lines of the haplobank are expected to cover approximately 30% of the southern Chinese population, offering an off-the-shelf approach for allogeneic transplantation of hiPSC-derived cell therapies.

She will be joined by Chao Sheng, who will introduce the established workflows from Miltenyi Biotec for automated and closed human PSC expansion and differentiation using the CliniMACS Prodigy® Adherent Cell Culture process and the iPS-Brew GMP Medium.

• Considerations for generating clinical-grade induced pluripotent stem cells (iPSCs)
• Prospects for using iPSCs as universal allogenic resources for advanced therapies
• How to realize PSC expansion and differentiation using a closed and automated system

Camie Chan

CEO at Xellera Therapeutics

Camie received her MSc in Medical Sciences and PhD in Immunology from the University of Toronto, followed by her postdoctoral fellowship at the Sydney Kimmel Cancer Research Center of Johns Hopkins University. She subsequently became Assistant Professor at the University of California, Davis in 2006. She has received numerous research funding and awards including the National Institute of Allergy and Infectious Diseases (NIAID) Developmental Research Grant and the University of California Cancer Research Award. In 2016, she joined Novoheart, a global biotech company specializing in bioengineered human hearts for disease modeling and drug discovery, as the Chief Operating Officer. In 2019, she joined Xellera Therapeutics as Chief Operating Officer and has spearheaded the first commercial cGMP facility for cell and gene therapy products in Hong Kong.

Chao Sheng

Expert for Regenerative Medicine Manufacturing at Miltenyi Biotec

Chao conducted his PhD projects at the Chinese Academy of Sciences in Beijing, China. He then continued his postdoctoral research at the University of Bonn and the German Center for Neurodegenerative Diseases in Bonn, Germany, where he established human stem cell models for his research on cellular fate reprogramming, disease modeling, and drug discovery. Chao joined Miltenyi Biotec in 2018, and currently, works with his colleagues to develop automated, closed, and scalable manufacturing solutions for human pluripotent stem cells and their derivatives on the CliniMACS Prodigy® platform.

Watch now

SPEAKERS

Camie Chan

CEO at Xellera Therapeutics

Chao Sheng

Expert for Regenerative Medicine Manufacturing at Miltenyi Biotec

You might also like

Comparing activation methods to yield clinical-scale expansion of gamma delta T cells

Chengkang Zhang

24 September

Watch

Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Sunil Acharya

1 August

Watch

CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform

Kunal Patel

10 July

Watch

Accelerate the scale-up to clinical phase: optimizing stem cell culture performance and viral vector titers

Sara Bursomanno

24 April

Watch

Positioning early cell therapy programs for clinical success: insights to mitigate risk and ensure GMP readiness

K Watanabe, M Sadik, M Duggan

7 March

Watch